Genomictree, Inc, 44-6 Techno 10-ro Yuseong-gu, Daejeon, 34027 South Korea.
Department of Pathology, College of Medicine, Soonchunhyang University, 23-20 Byeongmyeong-dong Dongnam-gu, Cheonan, Chungcheongnam-do 31151 South Korea.
Clin Epigenetics. 2017 Dec 4;9:126. doi: 10.1186/s13148-017-0426-3. eCollection 2017.
Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, which has emerged as a new epigenetic biomarker for early detection of CRC. Previously, we reported that we identified that CpG sites of were aberrantly methylated in tumor tissues of most CRC patients through comprehensive methylation analysis and demonstrated a high potential of quantification of methylation in blood for early detection of colorectal cancer. In this study, we aim to investigate the feasibility of quantifying methylation in stool DNA for the early detection of CRC. The objective of this study was to confirm a high frequency of methylation in tumor tissues at various stages of CRC and investigate the feasibility of a quantitative test for methylation in fecal DNA by highly sensitive and accurate real-time PCR for early detection of CRC.
Bisulfite-pyrosequencing assay was performed to measure the methylation status in tissue samples. For methylation analysis in stool DNA, a highly sensitive and accurate method was applied which implements consecutive two rounds of PCR consisting of unidirectional linear target enrichment (LTE) of and quantitative methylation-specific real time PCR (qMSP) for , named as me LTE-qMSP assay. Its limit of detection was 0.1% methylation (corresponding to ~ 6 copies in total ~ 6200 genome copies).
Positive methylation was observed in 100% of primary tumors, 90.6% of adenomatous polyps, 94.1% of hyperplastic polyps, and 0% of normal tissues. methylation level also significantly ( < 0.01) increased according to the severity of lesions. In stool DNA test for methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) ( = 50) and precancerous lesions ( = 21) with healthy subjects ( = 22), the overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%.
Taken together, our result indicates that stool DNA-based methylation test by LTE-qMSP is a potential noninvasive diagnostic tool for early detection of CRC.
结直肠癌(CRC)筛查是降低疾病相关死亡率的最有效策略。已知在 CRC 发展的早期,某些基因中会出现频繁的异常 DNA 甲基化,这已成为 CRC 早期检测的新表观遗传生物标志物。此前,我们通过全面的甲基化分析报告称,我们在大多数 CRC 患者的肿瘤组织中发现了 基因的 CpG 位点异常甲基化,并证明了血液中 甲基化的定量检测具有很高的潜力,可用于结直肠癌的早期检测。在这项研究中,我们旨在研究定量检测粪便 DNA 中 甲基化用于 CRC 早期检测的可行性。本研究的目的是确认 CRC 各个阶段肿瘤组织中 甲基化的高频率,并通过高度敏感和准确的实时 PCR 检测粪便 DNA 中 甲基化的定量检测来研究其可行性,用于 CRC 的早期检测。
采用亚硫酸氢盐-焦磷酸测序法检测组织样本中的 甲基化状态。用于粪便 DNA 甲基化分析的方法是一种高度敏感和准确的方法,它采用了两轮连续 PCR,包括 的单向线性靶向富集(LTE)和定量甲基化特异性实时 PCR(qMSP),称为 meLTE-qMSP 检测。其检测限为 0.1%的甲基化(对应于总约 6200 个基因组拷贝中的~6 个拷贝)。
在 100%的原发性肿瘤、90.6%的腺瘤性息肉、94.1%的增生性息肉和 0%的正常组织中观察到阳性 甲基化。根据病变的严重程度,甲基化水平也显著增加(<0.01)。在比较 CRC 患者(I-IV 期)(n=50)、癌前病变(n=21)与健康对照者(n=22)的粪便 DNA 中通过 LTE-qMSP 检测 甲基化的试验中,检测 CRC 的总体敏感性为 90.0%,检测小息肉的敏感性为 33.3%,特异性为 90.9%。
总之,我们的结果表明,基于 LTE-qMSP 的粪便 DNA 甲基化检测可能是 CRC 早期诊断的一种潜在的非侵入性诊断工具。